Biostrategies LC
Jonesboro, AR
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Neurogt Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bedrock Therapeutics, Inc. | Raleigh, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gigamune, Inc. | San Francisco, CA | — |
| Aavogen Inc. | Rockville, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Impedx Diagnostics | Columbia, MO | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Biostrategies LC is a for-profit, veteran-owned limited liability company located at Arkansas State University's Biosciences Institute in Jonesboro, Arkansas. The company specializes in advanced biotechnology research, focusing on developing innovative gene therapy and enzyme replacement therapies for rare genetic disorders. Its primary expertise lies in creating novel therapeutic approaches that can effectively deliver enzymes across complex biological barriers, particularly the blood-brain barrier, to treat devastating neurological and genetic conditions.
Biostrategies LC has secured multiple federal grants from key National Institutes of Health (NIH) institutes, including the National Eye Institute, National Institute of Child Health and Human Development, and National Institute of Neurological Disorders and Stroke. Their grant-funded research targets specific rare genetic disorders such as GM1 gangliosidosis, Morquio A syndrome (MPS-IVA), Sanfilippo A syndrome (MPS IIIA), and Krabbe disease. The company's innovative approach involves developing advanced gene therapy techniques that use adeno-associated virus (AAV) vectors combined with a lectin-based delivery technology (RTB) to produce functional replacement enzymes. These therapies aim to systematically deliver corrective enzymes across the blood-brain barrier, potentially offering the first effective treatments for these debilitating genetic disorders. Their research focuses on creating therapeutic interventions that can prevent neurological degradation, improve patients' quality of life, and potentially extend life expectancy for individuals with these rare genetic conditions.
SBA capabilities narrative
Research, development, and manufacture of plant-based bioproduction of human and agricultural vaccines, therapeutics, and neutraceuticals.
Quick answers
Is Biostrategies LC registered in SAM.gov?
Yes. Biostrategies LC's SAM.gov registration is active through February 27, 2027.
What is Biostrategies LC's CAGE code?
Biostrategies LC's CAGE code is 4BJ87, and its Unique Entity ID (UEI) is PE6MEQZRFW63.
What is Biostrategies LC's most recent federal award?
Biostrategies LC's most recent federal grant award is Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme - biostrategies… (R44NS141514), from National Institute of Neurological Disorders and Stroke (NIH), on September 15, 2025.
On GovTribe
See Biostrategies LC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors